It is generally accepted that recent advances in anticancer agents have contributed
significantly to the improvement of both the disease-free survival and quality of life in cancer …

New data indicate that primary dysfunction in the tumour microenvironment, in addition to
epithelial dysfunction, can be crucial for carcinogenesis. These recent findings make a …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …

Cyclin-dependent kinases (CDK) are key positive regulators of cell cycle progression and
attractive targets in oncology. SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity …

Since 1991, the NAD (P) H-aided conversion of resazurin to fluorescent resorufin has been
widely used to measure viability based on the metabolic activity in mammalian cell culture …

BACKGROUND: Evaluation of response to treatment is a key aspect in cancer therapy.
Response Evaluation Criteria in Solid Tumors (RECIST) are used in most oncology trials …

The development of novel molecularly targeted cancer therapeutics remains slow and
expensive with many late-stage failures. There is an urgent need to accelerate this process …

Identification of novel anti-cancer compounds with high efficacy and low toxicity is critical in
drug development. High-throughput screening and other such strategies are generally …

Cancer is the second cause of death worldwide, exceeded only by cardiovascular diseases.
The prevalent treatment currently used against metastatic cancer is chemotherapy. Among …

Background: With the advancement in biomedicine, many biologically targeted therapies
have been developed. These targeted agents, however, may not work for everyone …